LY294002 inhibits the malignant phenotype of osteosarcoma cells by modulating the phosphatidylinositol 3‑kinase/Akt/fatty acid synthase signaling pathway in vitro

Zhou,Yang; Zhu,Liang  Bo; Peng,Ai  Fen; Wang,Tao  Fang; Long,Xin  Hua; Gao,Song; Zhou,Rong  Ping; Liu,Zhi  Li

doi:10.3892/mmr.2014.2787

LY294002 inhibits the malignant phenotype of osteosarcoma cells by modulating the phosphatidylinositol 3‑kinase/Akt/fatty acid synthase signaling pathway in vitro

Authors:
- Yang Zhou
- Liang Bo Zhu
- Ai Fen Peng
- Tao Fang Wang
- Xin Hua Long
- Song Gao
- Rong Ping Zhou
- Zhi Li Liu
View Affiliations

Affiliations: Department of Orthopedics, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, College of Humanities, Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi 330006, P.R. China, Department of Orthopedics, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: October 27, 2014 https://doi.org/10.3892/mmr.2014.2787
Pages: 1352-1357

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increasing evidence suggests that fatty acid synthase (FASN) is crucial in the carcinogenesis of various types of tumor. In addition, the phosphatidylinositol 3‑kinase (PI3K)/Akt signaling pathway, which is closely associated with cellular metabolism, affects cancer biology. However, whether the malignant phenotype of osteosarcoma (OS) cells is regulated by the PI3K/Akt/FASN signaling pathway and how the PI3K family specific inhibitor, 2‑(4‑morpholinyl)‑8‑phenyl‑chromone (LY294002) affects the malignant phenotype of OS cells remains to be elucidated. In the present study, U2‑OS and MG‑63 cells were treated with LY294002 and subsequently western blot analysis was used to examine Akt, p‑Akt and FASN protein expression. Additionally, FASN mRNA was detected by reverse transcription quantitative polymerase chain reaction. MTT and fluorescence‑activated cell sorting assays were used to assess proliferation and apoptosis. Migration and invasion were investigated using wound healing and transwell invasion assays. The results demonstrated that LY294002 suppressed the PI3K/Akt/FASN signaling pathway. However, the malignant phenotypes of OS cells mentioned above were significantly inhibited. The present results indicated that LY294002 inhibits the malignant phenotype of OS cells via modulation of the PI3K/Akt/FASN signaling pathway in vitro and may be a new therapeutic strategy for the management of OS.

View Figures

View References

1	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
2	Bacci G, Briccoli A, Rocca M, et al: Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 14:1126–1134. 2003. View Article : Google Scholar : PubMed/NCBI
3	Ta HT, Dass CR, Choong PF and Dunstan DE: Osteosarcoma treatment: state of the art. Cancer metastasis Rev. 28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
4	Kager L, Zoubek A, Potschger U, et al: Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 21:2011–2018. 2003. View Article : Google Scholar : PubMed/NCBI
5	Wang TF, Wang H, Peng AF, et al: Inhibition of fatty acid synthase suppresses U-2 OS cell invasion and migration via downregulating the activity of HER2/PI3K/AKT signaling pathway in vitro. Biochem Biophys Res Commun. 440:229–234. 2013. View Article : Google Scholar : PubMed/NCBI
6	Chen HJ, Lin CM, Lee CY, et al: Kaempferol suppresses cell metastasis via inhibition of the ERK-p38-JNK and AP-1 signaling pathways in U-2 OS human osteosarcoma cells. Oncol Rep. 30:925–932. 2013.PubMed/NCBI
7	Zhao Z, Wu MS, Zou C, et al: Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-kappaB pathway. Cancer Lett. 342:150–158. 2013. View Article : Google Scholar
8	Zhang S, Guo W, Ren TT, Lu XC, Tang GQ and Zhao FL: Arsenic trioxide inhibits Ewing’s sarcoma cell invasiveness by targeting p38 (MAPK) and c-Jun N-terminal kinase. Anticancer Drugs. 23:108–118. 2012. View Article : Google Scholar
9	Liu R, Li X, Gao W, et al: Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth and metastasis. Clin Cancer Res. 19:6802–6811. 2013. View Article : Google Scholar : PubMed/NCBI
10	Wang YH, Dong YY, Wang WM, et al: Vascular endothelial cells facilitated HCC invasion and metastasis through the Akt and NF-kappaB pathways induced by paracrine cytokines. J Exp Clin Cancer Res. 32:512013. View Article : Google Scholar
11	Zito CR, Jilaveanu LB, Anagnostou V, et al: Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One. 7:e313312012. View Article : Google Scholar : PubMed/NCBI
12	Shukla S, Bhaskaran N, Babcook MA, Fu P, Maclennan GT and Gupta S: Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway. Carcinogenesis. 35:452–460. 2013. View Article : Google Scholar : PubMed/NCBI
13	Li J, Cao B, Zhou S, et al: Cyproheptadine-induced myeloma cell apoptosis is associated with inhibition of the PI3K/AKT signaling. Eur J Haematol. 91:514–521. 2013. View Article : Google Scholar : PubMed/NCBI
14	Qin H, Du X, Zhang Y and Wang R: Platycodin D, a triterpenoid saponin from Platycodon grandiflorum, induces G2/M arrest and apoptosis in human hepatoma HepG2 cells by modulating the PI3K/Akt pathway. Tumour Biol. 35:1267–1274. 2014. View Article : Google Scholar
15	Liu ZL, Mao JH, Peng AF, et al: Inhibition of fatty acid synthase suppresses osteosarcoma cell invasion and migration via downregulation of the PI3K/Akt signaling pathway in vitro. Mol Med Rep. 7:608–612. 2013.
16	Long XH, Zhang GM, Peng AF, Luo QF, Zhang L, Wen HC, et al: Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro. Oncol Rep. Epub 2013/11/01. 2013.PubMed/NCBI
17	McKenna RJ, Schwinn CP and Higinbotham NL: Osteogenic sarcoma in children. CA Cancer J Clin. 16:26–28. 1966. View Article : Google Scholar : PubMed/NCBI
18	Fraser GM and Aterman K: Osteogenic Sarcoma in Young Children: A Case Report with Review of Literature. Can Med Assoc J. 87:74–78. 1962.PubMed/NCBI
19	Pearson D and Steward JK: Malignant disease in juveniles. Proc R Soc Med. 62:685–688. 1969.PubMed/NCBI
20	Iwamoto Y, Tanaka K, Isu K, et al: Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci. 14:397–404. 2009. View Article : Google Scholar : PubMed/NCBI
21	Meyers PA, Schwartz CL, Krailo M, et al: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
22	Jawad MU, Cheung MC, Clarke J, Koniaris LG and Scully SP: Osteosarcoma: improvement in survival limited to high-grade patients only. J Cancer Res Clin Oncol. 137:597–607. 2011. View Article : Google Scholar
23	Ferrari S, Smeland S, Mercuri M, et al: Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 23:8845–8852. 2005. View Article : Google Scholar : PubMed/NCBI
24	Semba S, Itoh N, Ito M, Harada M and Yamakawa M: The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells. Clin Cancer Res. 8:1957–1963. 2002.PubMed/NCBI
25	Chen Z, Yang L, Liu Y, et al: LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/Akt/mTOR signaling pathway. Mol Cell Biochem. 385:169–177. 2013. View Article : Google Scholar : PubMed/NCBI
26	Hu L, Zaloudek C, Mills GB, Gray J and Jaffe RB: In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res. 6:880–886. 2000.PubMed/NCBI
27	Wempe SL, Gamarra-Luques CD and Telleria CM: Synergistic lethality of mifepristone and LY294002 in ovarian cancer cells. Cancer Growth Metastasis. 6:1–13. 2013.PubMed/NCBI
28	Liu ZL, Wang G, Peng AF, Luo QF, Zhou Y and Huang SH: Fatty acid synthase expression in osteosarcoma and its correlation with pulmonary metastasis. Oncol Lett. 4:878–882. 2012.PubMed/NCBI
29	Porta R, Blancafort A, Casoliva G, et al: Fatty acid synthase expression is strongly related to menopause in early-stage breast cancer patients. Menopause. 21:188–191. 2013. View Article : Google Scholar : PubMed/NCBI
30	Tao BB, He H, Shi XH, et al: Up-regulation of USP2a and FASN in gliomas correlates strongly with glioma grade. J Clin Neurosci. 20:717–720. 2013. View Article : Google Scholar : PubMed/NCBI
31	Rahman MT, Nakayama K, Ishikawa M, et al: Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer. Oncology. 84:166–173. 2013. View Article : Google Scholar : PubMed/NCBI
32	Liu ZL, Wang G, Shu Y, Zou PA, Zhou Y and Yin QS: Enhanced antitumor activity of epirubicin combined with cerulenin in osteosarcoma. Mol Med Rep. 5:326–330. 2012.
33	Liu ZL, Zhou Y, Luo QF, et al: Inhibition of fatty acid synthase supresses osteosarcoma cell invasion and migration. Indian J Pathol Microbiol. 55:163–169. 2012. View Article : Google Scholar : PubMed/NCBI
34	Yeh CW, Chen WJ, Chiang CT, Lin-Shiau SY and Lin JK: Suppression of fatty acid synthase in MCF-7 breast cancer cells by tea and tea polyphenols: a possible mechanism for their hypolipidemic effects. Pharmacogenomics J. 3:267–276. 2003.PubMed/NCBI
35	Van de Sande T, De Schrijver E, Heyns W, Verhoeven G and Swinnen JV: Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res. 62:642–646. 2002.PubMed/NCBI